Tekla Life Sciences Investors
Price Action
Technical Summary
STAGE 2 UPTRENDTekla Life Sciences Investors is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 74), indicating performance broadly in line with the market. Earnings growth of 231% provides fundamental context to the price action. However, with RSI at 79, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $18.43 | +11.91% | ABOVE |
| 50 SMA | $17.95 | +14.96% | ABOVE |
| 100 SMA | $17.39 | +18.62% | ABOVE |
| 150 SMA | $17.26 | +19.53% | ABOVE |
| 200 SMA | $17.01 | +21.27% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is HQL in an uptrend right now?
HQL has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, HQL is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is HQL overbought or oversold?
HQL's RSI (14) is 79. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is HQL outperforming the market?
HQL has a Relative Strength (RS) Rating of 74 out of 99. HQL is performing about average compared to the market.
Where is HQL in its 52-week range?
HQL is trading at $20.63, which is 100% of its 52-week high ($20.68) and 99% above its 52-week low ($12.84).
How volatile is HQL?
HQL has a Beta of 0.72 and 52-week volatility of 22%. It's less volatile than the S&P 500 - generally more stable.